ATTR-CM Treatment Market Expected to Reach $45.08 Billion by 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Progress Between 2026 And 2030?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size has experienced remarkable growth in recent years. The market is projected to expand from $13.29 billion in 2025 to $17.03 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 28.1%. This historical growth is attributable to several key factors: improved disease awareness among cardiologists, a rise in the diagnosis of rare cardiomyopathies, the availability of targeted pharmacological therapies, the expansion of specialty cardiac care centers, and advancements in genetic screening technologies.
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market is anticipated to experience substantial growth in the upcoming years. Its valuation is projected to reach $45.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 27.6%. The expansion during this forecast period stems from factors such as the broadening of precision medicine strategies, the increasing development of next-generation gene-silencing therapies, heightened investments in drug pipelines for rare diseases, improved patient access to sophisticated cardiac diagnostics, and a stronger emphasis on disease-modifying treatments. Prominent trends observed in the forecast period encompass the increasing uptake of transthyretin stabilizer therapies, the rising application of RNAi-based treatment methods, a growing focus on early detection and continuous disease monitoring, the expansion of personalized treatment regimens, and increased funding for research into rare cardiac conditions.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
What Major Factors Are Driving The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Forward?
The market for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment is projected to expand moving forward, driven by the increasing occurrence of chronic diseases. Chronic conditions are enduring health issues that progress gradually and last for a minimum of a year, frequently necessitating continuous medical attention. The growing prevalence of these long-term illnesses is attributed to various elements, including an aging population, sedentary habits, unhealthy eating patterns, rising obesity rates, and exposure to environmental contaminants. Transthyretin amyloid cardiomyopathy treatment functions by stabilizing transthyretin, reducing amyloid accumulation, improving cardiac function, and alleviating symptoms, thereby enhancing the management of associated chronic conditions. For illustration, as per the Centers for Disease Control and Prevention (CDC), a US-based federal agency, in April 2025, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition in 2023. This prevalence reached 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Hence, the increasing prevalence of chronic diseases is a significant driver for the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
What Segment Categories Shape The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segment Landscape?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
Which Trends Are Impacting The Progress Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Major companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are dedicated to advancing innovative therapies for ATTR-CM, including oral prescription medications intended to target and stabilize transthyretin (TTR) proteins or diminish amyloid fibril buildup in the heart. Oral prescription medication denotes drugs prescribed by a healthcare provider for oral intake, typically as tablets, capsules, or liquid solutions. For instance, in November 2024, BridgeBio Pharma Inc., a US-based biotechnology company, obtained approval from the U.S. Food and Drug Administration for Attruby (acoramidis) for treating adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This medication stabilizes the TTR protein, which helps reduce heart-related deaths and hospitalizations. Clinical trials have indicated that it is well-tolerated and offers quick benefits by addressing the disease’s fundamental cause.
Who Are The Companies Operating Across The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Value Chain?
Major companies operating in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc
Get The Full Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report:
Which Region Is The Leading Market For The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market 2026, By The Business Research Company
Hypertrophic Cardiomyopathy Treatment Market Report 2026
Hypertrophic Cardiomyopathy Hcm Therapeutics Market Report
Cardiometabolic Diseases Market Report
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
